ARCHIVES

Lilly Suspends Phase III Trial Of Tasisulam in Melanoma

This article is from The Cancer Letter archive.

Vol. 34 No. 1 | January 28, 2011

Download PDF Visit The Full Archive

Related Articles

NCI Programs: Institute Funds 24 DNA Microarray Centers

September 24, 1999

In Brief: Robert Bast Succeeds Singleton As Director Of Duke Cancer Center; Robert Bell Deputy

August 14, 1987

House Encourages NCI To continue Leadership Role As Coordinator Of Cancer Program

October 8, 1999

Two-Year Remission While Taking Gleevec Puts Patients Into Normal Mortality Rate

March 25, 2011

Early HER2 Positive Patients At Higher Risk of Recurrence

January 30, 2009

Pesticides Not Linked To High Rates Of Breast Cancer.

May 18, 2001